Fulgent Genetics (FLGT) Stock
Clinical genetic testing provider with centralized lab infrastructure. Here's the price, business snapshot, and what's worth knowing about Fulgent Genetics in August 2026.
Fulgent Genetics (FLGT) is a clinical and research genetic testing company providing high‑throughput sequencing and molecular diagnostics across inherited disease, oncology and infectious disease testing. The firm operates centralised laboratories and a technology platform that automates sample processing, analysis and reporting. Revenue is generated from diagnostic test fees, research services and partnerships with biopharma and clinical laboratories. With a market capitalisation around USD 733.7m, it sits in the small‑to‑mid cap range and can offer growth exposure but also greater volatility. Key indicators investors watch include test volumes, reimbursement trends, lab utilisation and new test rollouts. Strengths include scalable infrastructure and a diversified service mix; principal risks include competition, changes in insurance reimbursement, regulatory scrutiny and variable public‑health testing demand. This is general educational information, not personal investment advice — suitability depends on your objectives and risk tolerance, and share values can fall as well as rise.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Fulgent Genetics' stock with a target price of $23.75, indicating possible growth.
Financial Health
Fulgent Genetics is performing well, showing strong revenue and cash flow, with a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth Drivers
Investors may watch test volumes, new test launches and biopharma partnerships as potential sources of growth, though volumes can be cyclical and outcomes uncertain.
Technology & Scale
Scalable lab automation and data platforms can support margin improvement and capacity expansion, balanced by operational and regulatory execution risks.
Market Exposure
Primarily exposed to clinical testing demand and US reimbursement dynamics, with potential international or research‑service opportunities; reimbursement shifts can materially affect revenue.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
